Acceledent System From Orthoaccel Technologies, Inc. Secures Medical Device Regulatory Clearance To

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
12th November 2009, 09:23am - Views: 680






Community Health OrthoAccel Technologies, Inc. 2 image










MEDIA RELEASE PR37042


AcceleDent System From OrthoAccel Technologies, Inc. Secures Medical Device Regulatory Clearance to

Market in Australia


HOUSTON, Nov. 12 /PRNewswire-AsiaNet/ --



acceleration device to enhance orthodontics, announced that its application to market and distribute the product for

sale was approved by Australia's Therapeutic Goods Administration (TGA) (http://www.tga.gov.au/). AcceleDent is

classified as an, "orthodontic appliance system," in Australia.





    AcceleDent is a simple, removable dental device that patients wear in the mouth for twenty minutes daily. It

generates a light microvibration force which modulates the bone tissue remodeling process and accelerates

orthodontic tooth movement. The device is hands-free and allows the user flexibility to carry out most routine tasks

during the twenty-minute use session. The first case in private practice was initiated last month in the United

Kingdom, OrthoAccel's first commercial market.


    Brent Tarver, VP Clinical Affairs at OrthoAccel, remarked, "We consider this regulatory clearance to be an

important part of our strategic plans, particularly as we begin focusing on the conclusion of the pivotal trial next

year for FDA clearance here in the United States." AcceleDent has been added to the Australian Register of

Therapeutic Goods (ARTG). Mike Kaufman, VP Business Development at OrthoAccel, added, "We will be

attending the World Federation of Orthodontists 7th International Orthodontic Congress

(http://www.wfosydney.com/) in February next year in Sydney. Australia is a progressive orthodontic market that is

very open to credible and meaningful new technologies."


    Results from the initial clinical trial demonstrated an overall tooth movement rate of 2.1 mm per month, which is

30% to 50% faster than what is reported in the literature. This same study further demonstrated the safety

of the AcceleDent System through a detailed measurement and statistical analysis of root resorption, yielding mean

values of below 0.5 mm. It should be noted that 0.5 mm is well below the level of 2 mm, or one-third of the

root length, considered clinically significant by researchers.


    Jeremy J. Mao, DDS, PhD (http://www.acceledent.com/company/scientific-advisory-board/) is the original

inventor of the core OrthoAccel technology and also currently serves as the Chairman of the Company's Scientific 

Advisory Board. He commented, "The Phase I Human Clinical Trial conducted at the University of Texas Dental

Branch in Houston validates our previously published animal data that serves as the foundation for the concept that 

orthodontic treatment can be safely accelerated." Dr. Mao also serves as the Director of the Tissue Engineering &

Regenerative Medicine Laboratory and Professor at the Columbia University College of Dental Medicine in New

York.


    OrthoAccel is presently controlling availability of AcceleDent in the United Kingdom to a select group of

orthodontic specialists before a broader release in October 2010. The Company reports plans to take a similar

approach with the Australian market.


    About OrthoAccel Technologies, Inc.

    Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently

engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic

treatment.


    About the AcceleDent System

    AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating

biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard

Community Health OrthoAccel Technologies, Inc. 3 image

orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works

complementary with all existing orthodontic technologies. AcceleDent is neither FDA cleared nor FDA approved;

it is currently investigational only in the United States. More information can be found at www.acceledent.com or

requested via info@orthoaccel.com


    Media Contact Michael K. Lowe, CEO +1-832-631-1659


    SOURCE: OrthoAccel Technologies, Inc.


    CONTACT: Michael K. Lowe, 

                       CEO of OrthoAccel Technologies, Inc.

                       +1-832-631-1659



To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article